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Abstract 
Introduction 
Approximately 5% of unselected breast cancer patients carry a germline mu-
tation (gBRCAm) in the BRCA1 and BRCA2 genes that repair double-
strand DNA breaks through homologous recombination. Olaparib, an oral 
poly ADP-ribose polymerase inhibitor (PARPi), incurs selective synthetic 
lethality in BRCA-deficient tumour cells by inhibiting single-strand DNA 
repair. In 2014, olaparib was approved in Europe and USA for the treatment 
of BRCA-mutated ovarian cancer. Olaparib is under evaluation as mono-
therapy for human epidermal growth factor receptor 2 (HER2)-negative, 
BRCA-mutated metastatic breast cancer (MBC) in phase III trials.  
Methodology 
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer. Quality assessment was conducted to assess 
the risk of bias at the study level based on the EUnetHTA internal validity 
for randomized controlled trials. Furthermore, the magnitude of clinically 
meaningful benefit that can be expected from olaparib was evaluated based 
on, both the original and an adapted version of the Magnitude of Clinical 
Benefit Scale developed by the European Society for Medical Oncology. 
Results of the OlympiAD trial 
An intent-to-treat population of 302 patients with a confirmed gBRCAm and 
HER2-negative MBC, previously treated with fewer than three chemothera-
py regimens, were randomly assigned to receive olaparib (n = 205) or physi-
cian’s choice of chemotherapy (n = 97; capecitabine, eribulin, or vinorelbine 
in 21-day cycles). At 14-months follow-up, overall survival did not show a 
statistically significant difference between groups. Compared with chemo-
therapy, olaparib increased median progression-free survival (PFS) by 2.8 
months by blinded independent central review (BICR), reduced the risk of 
disease progression and death by 42%, and reduced the risk of investigator-
assessed second progression by 43%. BICR-assessed objective response rate 
was 59.9% for olaparib versus 28.8% for chemotherapy. At 15.3 months, 
chemotherapy improved disease-specific quality of life. Adverse events 
(AEs), primarily anaemia, caused a dose interruption, reduction or discon-
tinuation in 50%, 27% and 5% of olaparib patients, respectively. Patients 
require monthly monitoring for haematological toxicity. 
Conclusion 
Overall, olaparib improves PFS and reduces the risk of progression in 
HER2-negative BRCA-mutated MBC relative to physician’s choice chemo-
therapy. OlympiAD results hold limited internal and external validity, and 
follow-up may be insufficient to capture the risk of recurrence or second 
primary development. Not all patients respond to olaparib yet some sporadic 
triple negative breast cancer (TNBC) display a BRCAness phenotype with-
out carrying a gBRCAm. While patients are selected based on a confirmed 
deleterious gBRCAm, there is currently no established biomarker for re-
sponse to PARPi. Clinical utility of olaparib may be limited as three mecha-
nisms of resistance have already been established, increasing use of plati-
num therapy in early TNBC may influence PARPi use, and the optimal 
PARPi-chemotherapy drug combination remains to be established.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is the olaparib? 
A0022 Who manufactures olaparib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has olaparib received marketing authorisation? 
Health problem and current use 
A0002 What is breast cancer? 
A0004 What is the natural course of breast cancer? 
A0006 What are the consequences of breast cancer for society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of breast cancer? 
A0003 What are the known risk factors for breast cancer? 
A0024 
How is breast cancer currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is breast cancer currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of olaparib on mortality? 
D0005 How does olaparib affect symptoms and findings (severity, frequency) of breast cancer? 
D0006 How does olaparib affect progression (or recurrence) of breast cancer? 
D0011 What is the effect of olaparib on patients ̕ body functions? 
D0012 What is the effect of olaparib on generic health-related quality of life? 
D0013 What is the effect of olaparib on disease-specific quality of life? 
Safety 
C0008 How safe is olaparib in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying olaparib? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of olaparib? 
A0021 What is the reimbursement status of olaparib? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Olaparib/Lynparza/AZD-2281/KU-59436 
 
B0001: What is olaparib? 
Olaparib, an oral poly(adenosine diphosphate-ribose-ribose) polymerase in-
hibitor (PARPi), traps PARP at sites of DNA damage, preventing the repair 
of single strand DNA breaks and causing double strand breaks (DSB). 
While homologous recombination (HR) is the most common means of re-
pairing DSB, cells that are HR-deficient initiate more error-prone pathways 
such as non-homologous end joining or single strand annealing causing ge-
nomic instability and cell death. BRCA1 and BRCA2 (BReast CAncer gene 1 
or 2) are tumour suppressor genes that encode proteins involved in the HR 
repair of DSB in DNA. The selective inhibition of PARP leads to synthetic 
lethality in tumour cells with deficiencies in HR repair such as germline 
mutations in BRCA1/2 that reduce the cell’s ability to repair damaged DNA 
[2-4].  
Olaparib is formulated as a 50 mg oral capsule and as 100 mg and 150 mg 
tablets [5-7]. The capsule formulation is approved for the treatment of 
BRCA-mutated advanced ovarian cancer at a dose of 400 mg twice daily in 
Europe and the United States (US) [6, 8]. The tablet formulation, recently 
approved in the US, was developed to reduce the dose units required and 
improve compliance [7]. However, the formulations are not bioequivalent 
[9]. A dose-finding study concluded that a 300 mg twice daily tablet dose (4 
x 150 mg tablets per day) best matched the 400 mg twice daily capsule dose 
in terms of efficacy and tolerability [7, 10, 11]. In phase III olaparib mono-
therapy studies, olaparib is administered as two 150 mg tablets taken twice 
daily, an hour before or two hours after a meal, until disease progression or 
unacceptable toxicity [8, 12]. 
Myriad Genetics developed the companion diagnostic BRACAnalysis CDx™ 
to identify patients with deleterious or suspected deleterious germline 
BRCA mutations (gBRCAm) who may benefit from olaparib treatment [13]. 
Patients require baseline and monthly monitoring for haematological toxici-
ty due to the risks for myelodysplastic syndrome (MDS) and acute myeloid 
leukaemia (AML). Dose interruptions or reductions are recommended for 
individuals with adverse reactions or moderate renal impairment. Olaparib 
may be discontinued in patients with pneumonitis, MDS or AML. Concomi-
tant use of strong CYP3A inhibitors or inducers should be avoided [7].   
 
A0022: Who manufactures olaparib? 
AstraZeneca  
 
 
second generation 
PARPi 
2 x 150 mg oral tablets 
twice/day 
genetic testing for 
gBRCAm 
haematological 
monitoring 
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3 Indication 
A0007: What is the target population in this assessment? 
Olaparib (Lynparza™) is indicated as monotherapy for patients with 
BRCA-mutated, human epidermal growth factor 2 (HER2)-negative meta-
static breast cancer (MBC). 
 
 
 
4 Current regulatory status 
A0020: For which indications has olaparib received marketing authorisa-
tion? 
On December 18, 2014, the first-in-class PARPi olaparib received market 
authorisation by the European Medicines Agency (EMA) for the mainte-
nance treatment of adults with platinum-sensitive, relapsed, BRCA-
mutated, high grade, serous epithelial ovarian, fallopian tube, or primary 
peritoneal cancer [14]. Initial approval was based on the results of the phase 
II trial, Study 19 [8, 15]. Europe implemented a risk management plan in-
volving several trials to monitor safety [16]. 
On December 19, 2014, the US Food and Drug Administration (FDA) ap-
proved olaparib as monotherapy for patients with deleterious or suspected 
deleterious gBRCAm advanced ovarian cancer, as detected by BRACAnaly-
sis CDx™, who were previously treated with three or more lines of chemo-
therapy [6, 13]. 
AstraZeneca plans to file a supplementary marketing application before the 
end of the year to expand the licensing indication to include BRCA-mutated 
MBC based on results of the OlympiAD trial [12, 17].  
 
 
 
5 Burden of disease 
A0002: What is breast cancer? 
Owing to the molecular pathogenesis of breast cancer, it is designated as a het-
erogeneous malignancy. It arises from the tissues of the breast and most 
commonly originates in the cells that line the ducts due to dysregulation of 
the cell cycle [18, 19]. BRCA-mutated breast cancer is associated with an 
earlier onset; a family history of several close relatives affected with breast, 
ovarian, prostate or pancreatic cancer; and ethnic populations with founder 
mutations [20, 21]. Approximately 5% of unselected breast cancer patients 
carry a germline mutation in the breast and ovarian cancer predisposition 
genes BRCA1 and BRCA2 involved in double-strand DNA repair by HR 
BRCA-mutated, HER2-
negative MBC 
EMA and FDA: 
authorised/approved for 
BRCA-mutated ovarian 
cancer in December 
2014 
FDA approval for 
olaparib monotherapy 
in ovarian cancer 
applying to expand 
licensed indication: 
BRCA-mutated MBC 
5% have gBRCAm-
breast cancer: early 
onset, family history, 
Ashkenazi Jewish 
descent 
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[22]. Up to 75% of women with BRCA1-mutated cancers, an estimated 
180,000 women worldwide, have triple-negative breast cancer (TNBC) that 
lacks expression of the hormone oestrogen and progesterone receptors (HR-
negative) and the absence of amplification of oncogene ERBB2 (HER2-
negative) that encodes human epidermal growth factor receptor 2 [23]. 
Women with a BRCA2 mutation most often have tumours that express oes-
trogen receptors (ER-positive) [24]. 
 
A0004: What is the natural course of breast cancer? 
Breast cancer typically arises when epithelial cells lining the milk ducts 
and/or lobules undergo aberrant cell growth due to cell cycle dysregulation. 
Breast cancer is staged from I through IV based on tumour size, and pres-
ence or absence of lymph node involvement and metastases (TNM) [25]. The 
TNM staging system involves important tumour characteristics as well as 
survival data to support the estimation of outcomes. It classifies tumours on 
the basis of the primary tumour characteristics (T), the presence or absence 
of regional lymph node involvement (N), and the presence or absence of dis-
tant metastases (M). The TNM staging system is especially relevant for in-
flammatory and stage IV breast cancer [26].  
Ductal carcinoma, the most common type of breast cancer, originates in the 
cells of the ducts. In the early stages, atypical cells confined to the milk 
ducts are termed stage 0, ductal carcinoma in situ (DCIS). Breast cancer 
that spreads from its origin in the ducts or lobules to surrounding tissue is 
called invasive breast cancer. Approximately 70–80% of breast cancers are 
diagnosed as stage I (localized to one area) or stage II (early locally ad-
vanced, invasive ductal carcinoma (IDC) or invasive lobular carcinoma 
(ILC). Stage III locally advanced breast cancer (LABC) includes tumours 
larger than 5 cm in diameter that involve the skin, underlying muscle, 
lymph nodes or inflammatory breast cancer (IBC). During stage IV, breast 
cancer cells travel through the blood or lymphatic system forming metastatic 
tumours in bone, liver, lungs and brain [25]. Cancer that has spread to dis-
tant parts of the body, referred to as metastatic breast cancer (MBC), has a 
five-year survival rate of less than 27% [27].   
 
A0006: What are the consequences of breast cancer for society? 
Globally, breast cancer is the most frequently diagnosed malignancy and the 
leading cause of cancer death in women worldwide. Approximately 30% of 
women diagnosed with early stage breast cancer develop advanced or MBC 
despite treatment [28]. Patients may progress or further metastasize causing 
significant cancer specific morbidity and mortality. In Austria, breast cancer 
is the 19
th
 leading cause of disability adjusted life years and accounts for ap-
proximately 28,000 (2.6% of total) life lost due to premature mortality [29]. 
The incidence of breast cancer is highest for higher socioeconomic groups, 
whereas survival is lowest in lower socioeconomic groups [30]. Since increas-
ing age is a risk factor for cancer, the incidence of breast cancer is likely to 
increase as the population ages.  
 
 
 
TNM staging system 
staged I-IV by 
invasiveness 
 
 
 
 
 
 
 
 
metastasize to bone, 
liver, lungs, brain; 5 year 
survival <27% 
leading cause of cancer 
death in women 
worldwide 
 
 
incidence increases as 
population ages 
Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer 
LBI-HTA | 2017 11 
A0023: How many people belong to the target population? 
About 30% of all malignant neoplasm cases in Austria are due to breast can-
cer. It is the most common cause of death due to cancer in females. The age 
standardised incidence rate for the European Standard Population (2013) is 
64.3 per 100,000 persons per year. In 2014, 5,454 persons were newly diag-
nosed with breast cancer in Austria, of whom approximately 98.0% were 
women. Moreover, around 86.0% of female breast cancer patients and 78.0% 
of male breast cancer patients (all stages are included) are alive at least five 
years after diagnosis [31].  
While the median age at diagnosis of breast cancer is 62 years (range 55 to 
64 years) [27], most BRCA-mutated breast cancers are diagnosed before 50 
years of age. Rates of BRCA-mutated breast cancers increase in early adult-
hood until age 30 or 40 years for women with BRCA1 mutations, and 40 to 
50 years for those with BRCA2 mutations [20]. Women with mutations in 
BRCA1 or BRCA2 have an increased risk for contralateral breast cancer and 
metachronous ovarian cancer [22]. The ten year risk of ovarian cancer is 
12.7% and 6.8% for women with BRCA1 and BRCA2 mutation-associated 
breast cancer, respectively [32]. Between 5.0% and 10.0% of the patients are 
primarily diagnosed with MBC that has spread to other parts of the body, 
e.g., bone, liver, lung and brain [33].  
 
A0005: What are the symptoms and the burden of breast cancer? 
Breast cancer is most commonly characterized by a hard, immovable, lump 
or mass in the breast with irregular borders [34-36]. Patients with LABC 
may experience swelling, dimpling or thickening of the skin, a change in 
shape or colour, nipple retraction or discharge, and pain in the breast or un-
derarm. Symptoms of MBC include swollen lymph nodes, bone pain or frac-
tures, headaches or seizures, shortness of breath or jaundice depending on 
the organs affected [25]. 
 
A0003: What are the known risk factors for breast cancer? 
Approximately one in eight, or 12.4% of women will develop breast cancer at 
some point during their lifetime [27]. Risk factors for developing breast can-
cer include increasing age, female gender, a personal or family history of 
breast cancer, Caucasian race, obesity, increased breast density, alcohol con-
sumption and cigarette smoking. Reproductive factors that increase risk of 
breast cancer include early menarche, nulliparity or older age at first birth, 
late menopause, and hormone replacement therapy. Up to 10% of breast 
cancers may be due to the inheritance of genetic alterations in BRCA1 and 
BRCA2. Inheritance of one mutated BRCA1 or BRCA2 allele confers a life-
time risk of breast cancer as high as 80% [20]. Up to age 80, breast cancer 
risk is 72% for women with a BRCA1 mutation and 69% for those with a 
BRCA2 mutation [20]. Genetic testing for BRCA1 and BRCA2 mutations 
helps identify unaffected high-risk women for prevention and surveillance. 
 
 
 
incident rate based on 
European Standard 
Population: 64.3 per 
100,000 persons/year 
median age at diagnosis 
of BRCA-mutated breast 
cancer patients:  
<50 years 
main symptoms: breast 
lump, thickening, pain 
main risk factors: 
increasing age, female 
gender, personal or 
family history of breast 
cancer, genetic 
alterations 
 
gBRCAm: up to 80% 
lifetime risk of breast 
cancer 
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A0024: How is breast cancer currently diagnosed according to published 
guidelines and in practice? 
Diagnostic mammography is an x-ray that uses small doses of radiation to 
make an image of the breast following abnormal results of a screening 
mammogram or clinical breast exam (CBE). A mammogram of both breasts 
is performed to define tumour size and assess whether the contralateral 
breast is affected. Breast magnetic resonance imaging (MRI) or ultrasound 
may also be performed to estimate tumour size and distinguish between a 
fluid-filled or solid mass. If breast cancer is suspected based on mammogra-
phy, a biopsy is performed where a sample of breast cells or tissue from the 
lump is examined to determine the presence of cancer cells, and hormone 
receptor (HR) or HER2 protein expression. HR status is an important factor 
in planning clinical management. In later stages, bone scans, blood tests, x-
rays, CT and PET scans may be conducted to determine whether breast can-
cer has spread to bone, liver, lungs or brain [25, 37].  
 
 
 
6 Current treatment 
A0025: How is breast cancer currently managed according to published 
guidelines and in practice? 
Generally, breast cancer can be treated by surgery, adjuvant irradiation or 
systemic therapies [38]. To determine which treatment strategy is the most 
suitable for the patient, several factors are important [25, 38]: 
 stage of cancer (AJCC TNM staging system) 
 grade of disease 
 tumour site 
 menopausal status 
 patient health 
 HR and HER2 status 
 proliferation rate estimated by means of a Ki67 test 
The treatment of stage ≤3 breast cancer, where no distant metastases have 
been detected, has a curative intention and is dependent on the eligibility of 
a breast-conserving therapy (BCT) and whether it is a clinically node-
negative breast cancer. For patients who are eligible for a BCT, the following 
treatment options in this sequence may be applied [38]: 
 primary neoadjuvant systematic therapy (node-negative breast can-
cer) 
 surgery (sentinel lymph node biopsy [SLNB]) 
 axillary node dissection 
 adjuvant systematic therapy  
 adjuvant radiation therapy 
For patients who are not eligible for a BCT and for locally ABC (stage IIB, 
IIIA/B) the previously mentioned treatment options can be applied as well. 
However, instead of a BCT, a mastectomy may be performed. In case of met-
astatic disease (stage IV), treatment with a palliative intent (systematic ther-
apy, best supportive care, etc.) can be used [38]. 
diagnostics: 
mammography, biopsy, 
HR status, bone, CT, PET 
scans 
factors for therapeutic 
decisions 
curative treatment 
options for stage ≤3 
breast cancer 
stage IV breast cancer 
treatment options with 
a palliative intent 
Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer 
LBI-HTA | 2017 13 
For women with BRCA-mutated breast cancer, goals include preventing re-
currence and second primary breast and ovarian cancer [21]. Both HR-
positive and HER2-negative breast cancers are associated with a better 
prognosis than HR-negative and HER2-positive disease. TNBC often have 
worse outcomes than other breast cancer subtypes due to the lack of efficacy 
of hormone and HER2 targeted therapies [30]. More than 75% of tumours 
arising in women carrying a BRCA1 mutation are TNBC [32]. While BRCA-
mutated breast cancer is treated using a combination of surgery, chemother-
apy and radiotherapy, there is no definitive chemotherapy regimen or ap-
proved treatments specifically targeted for patients with a deleterious BRCA 
mutation [32, 39, 40]. However, the following treatment options are available 
for this patient population: 
 Risk-reducing surgeries, including prophylactic mastectomy and sal-
pingo-oophorectomy significantly reduce the risk of developing 
breast and/or ovarian cancer and improve overall survival in BRCA1 
and BRCA2 mutation carriers [32, 41].  
 Chemoprevention strategies, including the use of tamoxifen reduces 
the risk of contralateral breast cancer among BRCA1 and BRCA2 
carriers after treatment for breast cancer [41]. 
 Chemotherapy regimens for patients with HER2-negative breast can-
cer include anthracycline-based regimens followed or preceded by a 
taxane, and nonanthracycline-containing regimens. In addition to 
standard anthracycline- and taxane-based therapy, women may re-
ceive cyclophosphamide or gemcitabine or capecitabine with docet-
axel followed by docetaxel [39].  
 TNBC patients receive standard anthracycline- (doxorubicin or epi-
rubicin) and taxane-based (docetaxel or paclitaxel) chemotherapy 
regimens as adjuvant or neoadjuvant treatment. Due to the involve-
ment of BRCA genes in DNA repair, BRCA1-mutated breast cancer 
is more sensitive to platinums (cisplatin and carboplatin) compared 
to BRCA-proficient breast cancers. Neoadjuvant cisplatin treatment 
in BRCA1-mutated breast cancer demonstrated higher pathological 
complete response (PCR) compared to other chemotherapies. Higher 
PCR rates were also observed when carboplatin was added to an-
thracycline- and taxane-based neoadjuvant chemotherapy in TNBC 
[32, 39].  
 
 
 
7 Evidence 
A literature search was conducted on 07 August 2017 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “olaparib”, “lynparza”, “L01XX46”, “breast cancer”, 
“breast neoplasms”, “mamma carcinoma”, “metastatic” and “BRCA”. The 
manufacturer was also contacted and submitted six references (five of which 
had already been identified by systematic literature search, and a phase II 
study involving patients with various advanced cancers [42]). A manual 
search yielded three FDA reports [6, 7, 13], two EMA reports [14, 16], one 
clinical efficacy study [43], five clinical guidance documents [20, 25, 37, 39, 
treatment: surgery, 
chemotherapy, 
radiotherapy, no 
definitive regimen or 
treatment for BRCA-
mutated breast cancer 
TNBC treatment: 
adjuvant or neo-
adjuvant anthracycline- 
and taxane-based 
chemotherapy 
BRCA1-mutated breast 
cancer: sensitive to 
platinums 
systematic literature 
search in 5 databases:  
160 hits 
 
 
manual search: 14 
additional references 
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41], three statistical documents [27, 29, 31], and a cost document [44]. Ongo-
ing trials information was found on clinicaltrials.gov and EU Clinical Trials 
Register. Overall, 175 references were identified. 
Included in this reported are the following four studies to assess outcomes 
on clinical efficacy and safety:  
 OlympiAD, phase III study [22, 45] 
 ICEBERG 1, proof of concept, phase II study [46] 
 Olaparib in patients with known BRCA mutation status and recur-
rent ovarian cancer or TNBC, phase II study [43] 
 Olaparib monotherapy in advanced cancers with BRCA1 and 
BRCA2 mutations, phase II study [42] 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [47]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patient and treating physician, selective 
outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 5 of the Appendix. 
To evaluate the magnitude of “clinically meaningful benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [48]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [49]. Details of the magnitude 
of the clinically meaningful benefit scale are reported in Table 3. 
 
7.1 Clinical efficacy and safety – Phase III studies 
OlympiAD (NCT02000622) [12, 45] is an open-label, randomized, multicen-
tre, phase III study involving 302 patients with a gBRCAm and HER2-
negative MBC who had received no more than two previous chemotherapy 
regimens for metastatic disease. Efficacy data were analysed on an intention-
to-treat (ITT) basis, and safety was assessed in all patients who received at 
least one dose of the assigned treatment.  
Study participants were adults with a deleterious gBRCAm and histological-
ly or cytologically confirmed HER2-negative MBC; Eastern Cooperative 
Oncology Group (ECOG) performance status 0–1; with adequate bone mar-
row, kidney and liver function; previously treated with no more than two 
chemotherapy regimens for metastatic disease. Prior platinum treatment 
was allowed provided at least 12 months had elapsed prior to study entry. 
HR-positive patients must have progressed on at least one endocrine therapy 
or have disease that is believed to be inappropriate for endocrine therapy. A 
deleterious or suspected deleterious gBRCAm was confirmed by central test-
ing with BRACAnalysis (Myriad Genetics) in all but five cases. Patients who 
had previously received PARPi therapy, had untreated or uncontrolled brain 
metastases, HIV, or were pregnant or breast-feeding were excluded from 
study. Eligible patients were stratified according to previous use of chemo-
therapy for metastatic disease, HR-status (HR-positive versus TNBC), and 
previous use of platinum-based therapy.  
overall: 175 references 
included: 4 studies 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
OlympiAD: olaparib 
versus chemotherapy in 
302 patients with BRCA-
mutated HER2-negative 
MBC 
ITT stratified by HR-
status and previous 
chemotherapy 
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Patients were randomized 2:1 to receive olaparib tablets (300 mg twice daily) 
or 21-day cycles of physician’s choice chemotherapy with capecitabine (2,500 
mg/m
2
 oral daily for 14 days), eribulin (1.4 mg/m
2
 IV on days 1 and 8) or vi-
norelbine (30 mg/m
2
 IV on days 1 and 8) until disease progression or unac-
ceptable toxicity. The median total treatment duration was 8.2 months 
(range 0.5–28.7) in the olaparib group and 3.4 months (range 0.7–23.0) in the 
chemotherapy group. The median duration of follow-up was 14.5 months 
(range 2.1–29.5) for the olaparib group and 14.1 months (range 0.0–28.2) for 
the chemotherapy group.  
The primary endpoint was progression-free survival (PFS) as assessed by 
blinded independent central review (BICR) according to RECIST 1.1 or 
death due to any cause. At the time of data cut-off for the primary endpoint, 
77.5% of patients had disease progression or had died. A pre-specified sensi-
tivity analysis was based on investigator assessment. Secondary outcomes in-
cluded overall survival (OS), time from randomization to second progression 
(PFS2), objective response rate (ORR), health related quality of life 
(HRQoL), and safety. HRQoL was assessed using the 30-item European Or-
ganization for Research and Treatment of Cancer Quality of Life Question-
naire (QLQ-C30). Ranging from 0 to 100, higher QLQ-C30 scores indicate a 
better quality of life; where an increase or decrease of at least 10 points is 
considered a clinically meaningful change. Tumours were assessed at base-
line, every 6 to 8 weeks for 6 months, then every 12 weeks up to 7 years.  
The ITT population (n = 302; 205 olaparib vs 97 chemotherapy) had a me-
dian age of 44 years, 2.3% were male, 65.2% were Caucasian, 50% had 
TNBC, 77% had two or more metastatic sites, 71% had prior chemotherapy 
for MBC and 28% had prior platinum-based therapy in the neoadjuvant, ad-
juvant, or metastatic setting. Mean QLQ-C30 (±SD) scores at baseline were 
63.2±21.0 in the olaparib group and 63.3±21.2 in the chemotherapy group. 
Of the 97 patients assigned to chemotherapy, six patients declined treatment 
due to treatment allocation. While these patients were included in the effi-
cacy analysis, they were excluded from the safety analysis. Detailed patient 
characteristics, including inclusion and exclusion criteria are reported in 
Table 4 and study quality is described in Table 5 of the appendix, respec-
tively. Clinical efficacy data are presented in Table 1 and adverse events 
(AEs) are listed in Table 2.  
 
7.1.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of olaparib on mortality? 
At the time of analysis, December 9, 2016, a total of 94 (45.9% of) olaparib 
recipients and 46 (47.4% of) chemotherapy recipients had died. The median 
time to death was 19.3 months in the olaparib group and 19.6 months in the 
chemotherapy group. OS did not show a statistically significant difference 
between groups (hazard ratio [HR] for death 0.90, 95% CI 0.63–1.29; p = 
0.57). However, after the first progression event, more chemotherapy recipi-
ents than olaparib recipients received treatment with a PARPi, platinum-
based therapy or other cytotoxic chemotherapy.  
 
olaparib 300 mg 
twice/day vs 
chemotherapy IV every 
3 weeks; median follow-
up 14 months 
primary endpoint: PFS 
secondary endpoints: 
OS, PFS2, ORR, HRQoL, 
and safety 
ITT: median age 44 
years, 50% had TNBC, 
71% had prior 
chemotherapy, 28% had 
prior platinum therapy 
OS did not differ 
between groups 
 
median time to death: 
19.3 months for olaparib 
vs 19.6 months for 
chemotherapy 
Horizon Scanning in Oncology 
16 LBI-HTA | 2017 
D0006: How does olaparib affect progression (or recurrence) of breast can-
cer? 
Olaparib patients had a median PFS of 7.0 months compared to 4.2 months 
for chemotherapy recipients. Compared to standard chemotherapy with 
capecitabine, eribulin or vinorelbine, olaparib statistically significantly im-
proved PFS, as assessed by BICR (HR 0.58, 95% CI 0.43–0.80; p < 0.001). At 
12 months, 25.9% of olaparib patients and 15.0% of chemotherapy patients 
were free from progression or death. At the time of analysis, when 77% of 
data were mature, 52% of all patients had a second progression event or had 
died after a first progression event. The median time to PFS2 or death after 
a first progression event was 13.2 months in the olaparib group and 9.3 
months in the chemotherapy group. Compared to chemotherapy, olaparib 
improved investigator-assessed PFS2 (HR 0.57, 95% CI 0.40–0.83; p = 
0.003).  
 
D0005: How does olaparib affect symptoms and findings (severity, frequen-
cy) of breast cancer? 
Based on BICR, an objective response to treatment occurred in 100 of 167 
patients with measurable disease in the olaparib group (ORR 59.9%, 95% CI 
52.0–67.4) and 19 of 66 patients in the chemotherapy group (ORR 28.8%, 
95% CI 18.3–41.3). A complete response was seen in 9.0% of patients with 
measurable disease in the olaparib group and 1.5% of chemotherapy recipi-
ents. The median DOR was 6.4 months (interquartile range [IQR] 2.8–9.7) 
in the olaparib group and 7.1 months (IQR 3.2–12.2) in the standard chemo-
therapy group; median time to onset was 47 days and 45 days, respectively.  
 
D0011: What is the effect of olaparib on patients’ body functions? 
The most common laboratory abnormalities associated with olaparib use 
were anaemia (40%), neutropenia (27%), decreased white-cell count (16%), 
increased alanine aminotransferase (11%) and increased aspartate 
aminotransferase levels (9%). MDS/AML causing death occurred in less 
than 1.5% of patients exposed to olaparib monotherapy. Monthly 
haematological monitoring is recommended [7]. Less than 1% of patients 
developed pneumonitis requiring discontinuation of treatment [7].  
 
D0012: What is the effect of olaparib on generic health-related quality of 
life? 
D0013: What is the effect of olaparib on disease-specific quality of life? 
Among the 264 patients who completed the HRQoL QLQ-C30 question-
naire, at baseline and at least once thereafter, the adjusted mean (±SE) 
change from baseline across all time points was 3.9±1.2 in the olaparib 
group and -3.6±2.2 in the chemotherapy group (estimated difference 7.5, 
95% CI 2.5–12.4; p = 0.004). The median time to a clinically meaningful de-
crease in QLQ-C30 score (≥10 points) was not reached in the olaparib group 
and was 15.3 months in the chemotherapy group (HR 0.44, 95% CI 0.25–
0.77; p = 0.004).  
 
median BICR-assessed 
PFS: 7.0 months for 
olaparib vs 4.2 months 
for chemotherapy 
 
median investigator-
assessed PFS2: 13.2 
months for olaparib vs 
9.3 months for 
chemotherapy 
ORR: 59.9% for olaparib 
vs 28.8% for 
chemotherapy 
 
median DOR: 6.4 
months for olaparib vs 
7.1 months for 
chemotherapy 
increased risk of 
haematological toxicity, 
monitor monthly 
 
pneumonitis requiring 
discontinuation 
median time to a 
clinically meaningful 
improvement in QoL 
was not reached for 
olaparib and was 15.3 
months for 
chemotherapy  
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Table 1: Efficacy results of OlympiAD [22, 45] 
Descriptive statistics and 
estimate variability 
Treatment group Olaparib Chemotherapy 
Number of subjects 205 97 
PFS events, n (%) 
PFS events at 12 months, n (%) 
Median PFS, months 
163/205 (79.5) 
53/205 (25.9) 
7.0 
71/97 (73.2) 
15/97(15.0) 
4.2 
OS, n (%) 
Death, n (%) 
Median time to death, months 
111/205 (54.1) 
94/205 (45.9) 
19.3 
51/97 (52.6) 
46/97 (47.4) 
19.6 
PFS2 events, n (%) 157/302 (52) 
Median PFS2, months 13.2 9.3 
ORR, n (%) 
CR, n (%) 
Median DOR, months (IQR) 
Median time to response, days 
100/167 (59.9) 
15/167(9) 
6.4 (2.8–9.7) 
47 
19/66 (28.8) 
1/66 (1.5) 
7.1 (3.2–12.2) 
45 
HRQoL, n 
QLQ-C30 change from BL, ±SD 
191 
3.9±1.2 
73 
-3.6±2.2 
Time to QLQ-C30 ≥10 points NR 15.3 
Effect estimate per com-
parison 
Comparison groups Olaparib versus chemotherapy 
PFS by BICR1 HR 0.58 
95% CI 0.43–0.80 
Log-rank test p-value <0.001 
OS1 HR 0.90 
95% CI 0.63–1.29 
Log-rank test p-value 0.57 
PFS21 HR 0.57 
95% CI 0.40–0.83 
Log-rank test p-value 0.003 
QoL (n = 264) ED 7.5 
95% CI 2.5–12.4 
Log-rank test p-value 0.004 
Time to QLQ-C30 ≥10 points  
(n = 264) 
HR 0.44 
95% CI 0.25–0.77 
Log-rank test p-value 0.004 
Abbreviations: BL = baseline, BICR = blinded independent central review, CI = confidence interval, CR = complete response, DOR = 
duration of response, ED = estimated difference, HR = hazard ratio, HRQoL = health related quality of life, IQR = interquartile range, 
NR = not reached, ORR = objective response rate, PFS = progression-free survival, PFS2 = time from randomization to second progres-
sion or death, , SD = standard deviation, QLQ-C30 = 30-item European Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire, 
1
 = intention-to-treat population (n = 302) 
 
 
7.1.2 Safety 
 
C0008: How safe is olaparib in relation to the comparator(s)? 
The most common AEs of any grade associated with olaparib use were 
anaemia (40%), nausea (58%), vomiting (30%), fatigue (29%), neutropenia 
(27%), and diarrhoea (21%). Neutropenia (50%), palmar-plantar erythro-
dysesthesia (21%), and increased liver function enzymes (17%) of any grade 
occurred more frequently in the chemotherapy group. AEs of any grade were 
most common AEs: 
anaemia, nausea, 
vomiting, fatigue, 
neutropenia and 
diarrhoea 
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experienced by 97% of patients in both groups (199/205 olaparib and 88/91 
chemotherapy patients). The rates of grades 3, 4, and 5 AEs were 37%, 3% 
and 0% for olaparib versus 51%, 12% and 1% for chemotherapy, respective-
ly. Other grade 3 or higher AEs occurring in at least 2% of patients in either 
group were leukopenia (2% vs 3%), dyspnoea (1% vs 3%), and decreased 
platelet count (2% vs 1%) of olaparib versus chemotherapy patients, respec-
tively. A case of sepsis in an olaparib recipient and dyspnoea with disease 
progression in a chemotherapy recipient occurred both resulted in death. 
One new primary cancer, melanoma in situ, developed in an olaparib recipi-
ent with known medical history of skin melanoma.  
 
C0002: Are the harms related to dosage or frequency of applying olaparib? 
The median relative dose intensity, defined as the percentage of the actual 
dose intensity delivered relative to the intended dose intensity through to 
treatment discontinuation was 99.5% (IQR 89.5–100.0; mean 92.3%) for 
olaparib patients and 92.4% (IQR 77.4–99.0; mean 89.3%) for chemotherapy 
patients. Approximately 50% (102/205) of olaparib patients had a dose 
interruption, 27% (55/205) had a reduction in dose and 5% (10/205) 
discontinued treatment due to AEs. In the chemotherapy group, 31% 
(28/91) had a dose reduction due to AE, 28% (25/91) experienced a delay in 
treatment, and 8% (7/91) discontinued treatment.  
Dose reduction was primarily due to anaemia (14% of patients) in the 
olaparib group and to palmar-plantar erythrodysesthesia (8% of patients) in 
the chemotherapy group. Other AEs causing dose reductions in two or more 
olaparib recipients include neutropenia (5%), fatigue (2%), leukopenia 
(2%), increased alanine aminotransferase (2%), decreased platelet count 
(2%), thrombocytopenia (2%), increased aspartate aminotransferase (1%), 
nausea (1%), decreased neutrophil count (2%), and decreased white blood 
cell count (1%).  
While 2% of patients in both groups discontinued treatment due to anaemia, 
olaparib recipients also discontinued due to decreased platelet count, 
increased intracranial pressure, abdominal pain, dyspnea, erythma 
nodosum, and thrombocytopenia (0.5% for all). Chemotherapy patients also 
discontinued due to neutropenia, leukopenia, decreased neutrophil count, 
radiation skin injury, plamer-plantar erythrodysesthesia, peripheral moter 
neuropathy and vomiting (1% for all). 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of olaparib? 
Patients with moderate renal impairment (CLcr 31–50 ml/min) are at in-
creased exposure and should receive a reduced dose of 200 mg (2 x 100 mg 
tablets) twice daily, for a total daily dose of 400 mg. No statistically signifi-
cant difference in safety was noted for patients above versus below 65 years 
of age. However, there is no evidence regarding the use of olaparib in pa-
tients over 85 years or those with moderate or severe hepatic impairment.  
Females are advised to use effective contraception during olaparib treatment 
and for 6 months following completion of therapy based on the potential for 
foetal toxicity. Women are also advised not to breastfeed during treatment 
and for one month following their last dose [7].  
27% and 5% olaparib vs 
31% and 8% of 
chemotherapy patients, 
respectively, required 
dose reduction or 
discontinuation due to 
anaemia  
dose reductions in the 
olaparib group mostly 
due to anaemia 
in both groups 2% of 
patients discontinued 
therapy due to anaemia  
dose reduction for 
patients with renal 
impairment 
olaparib may cause 
genotoxicity and foetal 
harm 
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Table 2: Most frequent adverse events of OlympiAD [22, 45]  
 
Adverse Event (according  
to CTCAE version 4.0) 
 
Olaparib (n = 205) Chemotherapy (n = 91) 
 Any Grade  
n (%) 
Grade ≥3 
n (%) 
Any Grade  
n (%) 
Grade ≥3 
n (%) 
Any AE 199 (97.1) 75 (36.6) 88 (96.7) 46 (50.5) 
Anaemia 82 (40.0) 33 (16.1) 24 (26.4) 4 (4.4) 
Neutropenia 56 (27.3) 19 (9.3) 45 (49.5) 24 (26.4) 
Decreased white-cell count 33 (16.1) 7 (3.4) 19 (20.9) 9 (9.9) 
Nausea 119 (58.0) 0 (0) 32 (35.2) 1 (1.1) 
Vomiting 61 (29.8) 0 (0) 14 (15.4) 1 (1.1) 
Diarrhoea 42 (20.5) 1 (0.5) 20 (22.0) 0 (0) 
Decreased appetite 33 (16.1) 0 (0) 11 (12.1) 0 (0) 
Fatigue 59 (28.8) 6 (2.9) 21 (23.1) 1 (1.1) 
Headache 41 (20.0) 2 (1.0) 14 (15.4) 2 (2.2) 
Pyrexia 29 (14.1) 0 (0) 16 (17.6) 0 (0) 
Cough 35 (17.1) 0 (0) 6 (6.6) 0 (0) 
Increased alanine 
aminotransferase level 
23 (11.2) 3 (1.5) 16 (17.6) 1 (1.1) 
Increased aspartate 
aminotransferase level 
19 (9.3) 5 (2.4) 15 (16.5) 0 (0) 
Palmar-plantar 
erythrodysesthesia 
1 (0.5) 0 (0) 19 (20.9) 2 (2.2) 
Dose reduction due to AE 52 (25.4) NA 28 (30.8) NA 
Treatment interruption or 
delay due to AE 
72 (35.1) NA 25 (27.5) NA 
Treatment discontinuation 
due to AE 
10 (4.9) NA 7 (7.7) NA 
Abbreviations: AE = adverse event, CTCAE = Common Terminology for Cancer Adverse Events, NA = not applicable 
 
 
7.2 Clinical effectiveness and safety – further studies 
ICEBERG 1 (NCT00494234) is a multicentre, open-label, sequential cohort, 
proof of concept phase II trial investigating the efficacy, safety and tolerabil-
ity of olaparib monotherapy assigned to 54 women with BRCA-mutated ad-
vanced breast cancer previously treated with chemotherapy. The first cohort 
(n = 27) received continuous oral olaparib at the maximum tolerated dose 
(400 mg twice daily) and the second cohort (n = 27) received a lower dose 
(100 mg twice daily) for 168 days. The median number of prior chemothera-
py regimens was three (range 1–5 for cohort 1, 2–4 for cohort 2) [46].  
ICEBERG 1: 54 BRCA-
mutated advanced 
breast cancer patients 
receive maximum vs 
lower dose olaparib 
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Patients receiving the maximum dose (400 mg twice daily) had an ORR of 
41% (11/27, 95% CI 25–59) and patients receiving 100 mg twice daily had an 
ORR of 22% (6/27, 95% CI 11–41). The median duration of objective re-
sponse was 144 days (range 92–393) in cohort 1 and 141 days (55–175) in co-
hort 2. The median PFS was 5.7 months (95% CI 4.6–7.4) for cohort 1 and 
3.8 months (95% CI 1.9–5.5) for cohort 2. PFS events were reported in 96% 
(26/27) of patients in cohort 1 and 78% (21/27) patients in cohort 2. The 
most common treatment-related AEs in the maximum dose cohort were fa-
tigue (grade 1 or 2, 11 [41%]; grade 3 or 4, 4 [15%]), nausea (grade 1 or 2, 11 
[41%]; grade 3 or 4, 4 [15%]), vomiting (grade 1 or 2, 3 [11%]; grade 3 or 4, 3 
[11%]), and anaemia (grade 1 or 2, 1 [4%]; grade 3 or 4, 3 [11%]). The most 
frequent causally related AEs in the lower dose cohort were nausea (grade 1 
or 2, 11 [41%]; none grade 3 or 4) and fatigue (grade 1 or 2, 7 [26%]; grade 3 
or 4, 1 [4%]) [46].  
Olaparib was investigated in 91 patients with advanced ovarian (n = 65), 
breast or TNBC (n = 26) with known BRCA mutation status 
(NCT00679783) in a multicentre, open-label, non-randomized, correlative 
phase II study [43]. The study was designed to evaluate the ORR, assess ear-
ly markers of activity and to identify markers that correlate with a response. 
Patients received olaparib (400 mg twice daily) until disease progression and 
were stratified according to BRCA mutation status. In the breast cancer co-
horts, one (7%) of 15 women with TNBC had a BRCA mutation. Of the 11 
patients initially recruited into the mutation-positive cohort, four (36%) had 
TNBC, five (45%) had non-TNBC and two (19%) were reclassified as 
BRCA-negative after central screening favoured genetic variants rather than 
mutations. Median exposure to treatment in the breast cancer cohort was 56 
days (range 20–288 days).  
None of the breast cancer patients had an objective response. At 8 weeks, the 
disease control rate was 38% (95% CI 22–57; 10/26); 70% (40–89; 7/10) in 
the BRCA1 or BRCA2 positive cohort and 19% (7–43; 3/16) in mutation-
negative cohorts. While target lesions in five (50%) patients with BRCA1 or 
BRCA2 mutations were reduced in size by more than 30%, they were not 
confirmed objective responders as assessed by RECIST). PFS in patients 
with BRCA mutations was 109 days (range 95% CI 53–168 days), BRCA-
negative was 54 days (range 49–54 days), and in all those with breast cancer 
54 days (range 51-106 days). The most common treatment-related AEs in 
breast cancer patients were fatigue (50%), nausea (62%), vomiting (35%), 
and decreased appetite (27%) [43]. 
The efficacy and safety of olaparib monotherapy in advanced cancers with 
gBRCAm was investigated in 298 patients in a multicentre, non-randomised, 
phase II study (NCT01078662). Patients with platinum-resistant ovarian 
cancer (n = 193), breast cancer previously treated with more than three lines 
of chemotherapy for metastatic disease (n = 62), pancreatic cancer with pri-
or gemcitabine treatment (n = 23), prostate cancer with progression follow-
ing hormonal and systemic therapy (n = 8), or other solid tumours (n = 12) 
were treated with olaparib (400 mg twice daily). Of the 63 patients with 
breast cancer, the mean number of prior chemotherapy courses for metastat-
ic disease was 4.6 (SD 2; range 3–11), 68% had received prior platinum, 
more than 75% had received prior cyclophosphamide, doxorubicin or 
paclitaxel, and more than 45% had received fluorouracil, capecitabine, 
docetaxel or gemcitabine. 
ORR: 41% for maximum 
vs 22% for lower dose 
 
common treatment-
related AEs: fatigue, 
nausea, vomiting, and 
anaemia at maximal 
dosage 
phase II: olaparib for 
ovarian, breast and 
TNBCs (n = 26) with 
known BRCA status  
ORR: no confirmed 
objective response in 
breast cancer cohorts 
 
common AEs: fatigue, 
nausea, vomiting, 
decreased appetite 
phase II: olaparib 
monotherapy for 
advanced cancers with 
gBRCAm (n = 63 breast 
cancer)  
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The tumour response rate was 26.2% (78/298, 95% CI 21.3–31.6) overall and 
12.9% (8/62, 95% CI 5.7–23.9) for breast cancer, respectively. Stable disease 
≥ 8 weeks was observed in 42% of patients (95% CI 36.0–47.4), including 
47% (95% CI 34.0–59.9) of those with breast cancer, respectively. Overall 
median DOR was 204 days for breast cancer and time to onset of response 
was 54.5 days. Of the 32 patients with ER-positive breast cancer, 4 (12.5%, 
95% CI 3.5–29.0) had a tumour response to olaparib, compared with four of 
30 (13.3%, 95% CI 3.8–30.7) of those with ER-negative breast cancer. OS was 
11 months; 44.7% of breast cancer patients were alive at 12 months. Overall, 
the most common AEs were fatigue (48%), nausea (53%), and vomiting 
(34%). Serious AEs (grade ≥3) were reported in 25.8% of breast cancer pa-
tients, primarily due to anaemia (15%) [42].  
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of olaparib? 
In Austria, olaparib is available as 50 mg hard capsules in packages of 448 
pieces. One package of 448 50 mg capsules is available for € 5,059.29 (ex-
factory price). At the recommended dose of 300 mg tablets twice daily 
(equivalent dose of 400 mg capsules twice daily), the cost for olaparib treat-
ment would be € 3,794.47 per 21-day cycle [7, 10, 11, 44]. A median duration 
of 14.5 months (range, 2.1–29.5 months) of olaparib treatment would cost 
approximately € 75,889.40. Patients may be selected for therapy based on an 
FDA-approved companion diagnostic BRACAnalysis CDx™ for olaparib. 
Myriad Genetics have made an agreement with AstraZeneca to provide 
companion diagnostic BRCA testing for the olaparib phase III trial pro-
gramme [8].  
 
 
 
9 Ongoing research 
Several studies are ongoing to investigate olaparib as monotherapy for ad-
vanced or metastatic HER2-negative gBRCAm-positive breast cancer or 
TNBC following pre-treatment with chemotherapy, and in combination with 
immune checkpoint inhibitors or anticancer agents. In September 2017, a 
search of clinicaltrials.gov using search terms “olaparib” and “breast cancer” 
yielded 26 registered studies (three phase III, one phase 2/3, seven phase II, 
four phase I/II, eleven phase I). A search of the EU Clinical Trials Register 
yielded 13 studies (eleven were already identified in clinicltrials.gov; three 
phase III, one phase II/III, four phase II, and five phase I/II). Most studies 
are industry-sponsored or conducted in collaboration with industry.  
Selected ongoing phase III, II and I/II studies investigating olaparib for 
BRCA-mutated breast cancer patients: 
RR: 12.9% for breast 
cancer 
 
median DOR: 204 days 
 
OS: 11 months; 12-
month survival: 45% 
 
AEs: fatigue, nausea, 
vomiting, anaemia 
€ 3,797.47 per 21-day 
cycle 
 
 
 
 
€ 75,889.40 per 14.5 
months of olaparib 
treatment 
26 registered trials; 3 
industry-sponsored 
phase III studies 
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 NCT02681562: A phase II, randomized, controlled, open-label, 
study in patients with locally advanced HR-negative and HER2-
negative TNBC and locally advanced gBRCAm-positive breast can-
cer to correlate baseline gene expression and clinical response. Es-
timated primary completion date is January 2018. 
 NCT02789332: A phase II, prospective, randomized, open-label 
study evaluating the efficacy and safety of paclitaxel and olaparib 
compared to paclitaxel with carboplatin followed by epirubicin and 
cyclophosphamide as neoadjuvant chemotherapy in patients with 
HER2-negative early breast cancer and a deleterious gBRCAm. Es-
timated primary completion date is November 2018. 
 NCT02484404: A phase I/II, dose-escalation study investigating the 
anti-programmed death ligand-1 antibody (PD-L1) MEDI4736 in 
combination with olaparib and/or cediranib for advanced solid tu-
mours and/or recurrent ovarian, TNB, lung and colorectal cancers. 
Estimated primary completion date is December 2018. 
 NCT03167619: A phase II, randomized trial to assess the efficacy of 
olaparib in combination with durvalumab in platinum-treated met-
astatic TNBC. Estimated primary completion date is October 2019.  
 NCT02032823: A phase III, randomized, double-blind, placebo-
controlled, parallel group study to assess the efficacy and safety of 
olaparib versus placebo as adjuvant treatment in patients with 
gBRCA1/2 mutations and high risk HER2-negative primary breast 
cancer who have completed local treatment and neoadjuvant or ad-
juvant chemotherapy. Estimated primary completion date is March 
2020. 
 NCT03150576: A phase III, randomized, open-label neoadjuvant 
study to evaluate the safety and efficacy of concurrent platinum-
based chemotherapy with olaparib for TNBC in patients with a 
gBRCAm. Estimated primary completion date is January 2022. 
 
 
 
10 Discussion 
On December 18, 2014, olaparib received market authorisation in Europe 
and the US for the maintenance treatment of adults with platinum-sensitive, 
relapsed, BRCA-mutated advanced ovarian, fallopian tube or primary peri-
toneal cancer [14]. While initial approval was based on the results of the 
phase II trial, Study 19 [15], a risk management plan was implemented to 
monitor safety [16]. In December 2014, The FDA also approved olaparib as 
monotherapy for patients with deleterious gBRCAm advanced ovarian can-
cer, as detected by BRACAnalysis CDx™, previously treated with three or 
more lines of chemotherapy [6, 27]. Based on the results of the OlympiAD 
trial, the manufacturer plans to file a supplementary marketing application 
to expand the licensing indication to include BRCA-mutated MBC before 
the end of the year [12].  
EMA authorised /FDA-
approved for BRCA-
mutated ovarian cancer 
AstraZeneca filing 
expansion for BRCA-
mutated MBC 
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OlympiAD, a randomized, open-label, phase III study compared the safety 
and efficacy of olaparib (300 mg twice daily) versus chemotherapy (capecit-
abine, eribulin, or vinorelbine in 21-day cycles) in 302 patients with a 
gBRCAm and HER2-negative MBC who were previously treated with fewer 
than three chemotherapy regimens [12]. At a median follow-up of 14 
months, OS did not show a statistically significant difference between 
groups. Compared with chemotherapy, olaparib increased BICR-assessed 
median PFS by 2.8 months, reduced the risk of disease progression and 
death by 42%, and reduced the risk of investigator-assessed second progres-
sion by 43% in the ITT population. BICR-assessed ORR was 59.9% for 
olaparib versus 28.8% for chemotherapy, where olaparib conferred a shorter 
DOR (6.4 vs 7.1 months) and longer time of onset (47 vs 45 days) than 
chemotherapy. The median time to achieve an improvement in disease-
specific quality of life, based on a clinically meaningful decrease in QLQ-
C30 of ≥10 points, was not reached in the olaparib group and was 15.3 
months in the chemotherapy group [12, 45].  
The most common AEs were anaemia, nausea, vomiting, fatigue, neutro-
penia and diarrhoea. Approximately 50% of olaparib patients had a dose in-
terruption, 27% had a dose reduction and 5% discontinued treatment due to 
AEs compared to 31%, 28%, and 8% for chemotherapy patients, respective-
ly. Regardless, fewer AEs of grade 3 or higher were reported in the olaparib 
group compared to chemotherapy. Anaemia was the primary cause of dose 
reduction (14%) and treatment discontinuation (2%) in the olaparib group. 
Other AEs resulting in dose adjustment or discontinuation include neutro-
penia, fatigue, leukopenia, increased liver enzymes, decreased platelet 
count, decreased neutrophils and white blood cell count.  
The clinical efficacy and safety results of OlympiAD are consistent with 
phase II data from ICEBERG 1 and a study (NCT01078662) that investigat-
ed olaparib monotherapy for advanced cancers with gBRCAm [42, 46] where 
olaparib monotherapy resulted in an objective response and prolonged me-
dian PFS for women with BRCA-mutated advanced breast cancer previously 
treated with chemotherapy. However, the efficacy results of OlympiAD dif-
fer from those of a phase II study that investigated olaparib monotherapy in 
26 breast or TNBC patients of known BRCA mutation status where none of 
the breast cancer patients had an objective response to treatment [43]. While 
target lesions in 50% of patients with BRCA mutations were reduced in size 
by ≥30%, they were not confirmed objective responders as assessed by RE-
CIST. Differences in objective response may be due to chance based on the 
small sample size of Gelmon et al. the heavily pre-treated characteristics of 
these patients, and the fact that TNBC comprises a heterogeneous group 
where representation of a PARPi-sensitive BRCAness subgroup may be low 
in a small unselected population [43]. While the median time to a clinically 
meaningful decrease in QLQ-30 was not reached in the OlympiAD trial, 
olaparib prolonged quality–adjusted PFS and the duration without symp-
toms of disease or treatment toxicity for ovarian cancer patients compared to 
placebo [31]. Anaemia, fatigue, nausea, and vomiting were also the most 
commonly reported AEs in phase II trials [42, 43, 46]. 
Several methodological limitations of the OlympiAD compromise internal 
and external validity. While patients were randomized 2:1 olaparib versus 
chemotherapy via a centralized interactive voice/web response system that 
generated a random allocation sequence, allocation concealment was not 
maintained and may influence how participants were assigned to a given 
group. Internal validity may be compromised in an open-label study where 
OlympiAD: no 
statistically significant 
difference in OS, 
increased PFS (+2.8 
months), reduced risk of 
progression 
AEs requiring dose 
interruption were more 
common in the olaparib 
group 
inconsistency in OR 
compared to one former 
phase II study 
 
 
 
 
 
 
 
 
 
 
 
common AEs: anaemia, 
fatigue, nausea, and 
vomiting  
high risk of bias: unclear 
allocation concealment, 
open-label study  
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patients and treating physicians are aware of treatment allocation, and the 
physician chooses the chemotherapeutic comparator.  
Given the non-curative setting of olaparib and the statistically significant 
primary endpoint PFS we applied form 2b of the ESMO-MCBS in order to 
assess whether olaparib satisfies the criteria for a “meaningful clinical bene-
fit” (score 4 or 5). Both the original as well as the adapted version of the 
MCBS were applied [48, 49]. The application of the ESMO-MCBS to the 
OlympiAD study resulted in a grade 3 in the original as well as in the 
adapted version of the ESMO-MCBS, respectively. Therefore, olaparib does 
not lead to a meaningful clinical benefit in both scales. 
Results of the OlympiAD trial hold several limitations. While OS did not 
show a statically significant difference between groups, the study was not 
powered to assess differences in OS and OS could be confounded as more 
patients in the chemotherapy group than in the olaparib group received 
treatment with PARPi, platinum-based therapy, or other cytotoxic chemo-
therapy following a first progression event [12]. While anthracycline- and 
taxane-based chemotherapy regimens are considered standard treatment, 
because there is no definitive chemotherapeutic regimen for BRCA-mutated 
MBC, the addition of a platinum may also have served as an appropriate 
comparator [39]. Higher PCR rates have been observed when carboplatin 
was added to anthracycline- and taxane-based neoadjuvant chemotherapy in 
TNBC, and BRCA1-mutated breast cancers are more sensitive to cisplatin 
than BCRA-proficient breast cancers [32]. Approximately 50% of olaparib 
patients had a dose interruption due to AEs, primarily due to anaemia. For 
patients with moderate renal impairment, preference for treatment may lie 
with therapeutic options that pose less risk for haematological toxicities, 
MDS and AML.  
Other PARPis have shown some synthetic lethal activity in BRCA-mutant 
patients, including talazoparib (Biomarin), niraparib (Merck/Tesaro), 
rucaparib, (Clovis) and veliparib (Abbvie). Most trials exclude patients who 
were previously treated with platinums and investigate PARPi monotherapy 
compared to standard chemotherapy or PARPi in combination with chemo-
therapy in advanced disease and neoadjuvant therapy settings. Similar to 
OlympiAD, two phase III trials BRAVO (niraparib, NCT01905592) and 
EMBRACA (talazoparib, NCT02000622) are evaluating PARPi monothera-
py versus physician’s choice chemotherapy in patients with gBRCAm MBC. 
Another phase III study (NCT02163694) will investigate veliparib versus 
placebo in combination with carboplatin and paclitaxel in HER2-negative 
BRCA-mutated MBC. A phase II study is assessing rucaparib as adjuvant 
treatment for TNBC or HER2-negative BRCA-mutated breast cancers fol-
lowing preoperative chemotherapy (NCT01074970). The addition of velipa-
rib and carboplatin to standard neoadjuvant therapy for TNBC resulted in 
an estimated 52% PCR rate compared to 26% for standard therapy. While 
combination topotecan and olaparib resulted in dose-limiting haematologi-
cal AEs at sub-therapeutic doses, veliparib combinations have been better 
tolerated. The length of follow-up for most studies is insufficient to predict 
the risk of developing new primary malignancies, a major concern regarding 
drugs that inhibit DNA damage repair mechanisms [2, 4, 50].  
The cost of one package of 448 50 mg olaparib capsules is € 5,059.29 (ex-
factory price). At the recommended dose of 300 mg tablets twice daily (400 
mg capsules twice daily), the cost of olaparib treatment would be € 3,794.47 
per 21-day cycle [44]. A median duration of 14.5 months (range, 2.1–29.5 
ESMO-MCBS 
original: 3 
adapted: 3 
limitations: insufficient 
power to assess OS, 
confounded by 
treatments following 
first progression 
phase III trials of 
niraparib or talazoparib 
versus physician’s choice 
chemotherapy for 
patients with gBRCAm 
MBC; most exclude 
patients previously 
treated with platinum 
 
veliparib combinations 
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olaparib with topotecan 
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cycle; € 75,889.40 per 
14.5 months of 
treatment 
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months) of olaparib treatment would cost approximately € 75,889.40. Pa-
tients may be selected for therapy based on an FDA-approved companion 
diagnostic BRACAnalysis CDx™ for olaparib. Myriad Genetics have made 
an agreement with AstraZeneca to provide companion diagnostic BRCA 
testing for the olaparib phase III trial programme [8].  
Overall, the OlympiAD phase III randomized, open-label study reports that 
olaparib improves PFS and reduces the risk of progression in patients with 
HER2-negative BRCA-mutated MBC relative to physician’s choice chemo-
therapy following prior chemotherapy for metastatic disease. Not all pa-
tients with BRCA-associated breast cancer or TNBC respond to PARPi; 
however, some sporadic TNBC display a BRCAness phenotype without car-
rying a gBRCAm. Patients are selected for treatment based on a confirmed 
deleterious BRCA mutation and homologous recombination deficiency 
scores may identify those with HR deficiency; however, there is currently no 
established biomarker for response to PARPi. The length of follow-up may 
be insufficient to capture the risk of recurrence or the development of a sec-
ond primary cancer.  
The clinical utility of PARPi may be limited. Three mechanisms of re-
sistance to PARPi have already been established where the development of a 
secondary mutation restores BRCA functionality, drug efflux is increased by 
overexpression of P-glycoprotein, and a loss of p53 binding protein 1  reduc-
es sensitivity to PARPi. Increasing the use of platinum in early TNBC may 
also influence PARPi use given the overlapping mechanisms of action and 
resistance [4]. Veliparib exhibits a cytotoxic effect by suppressing PARPs’ 
catalytic activity while olaparib, talazoparib, rucaparib, and niraparib are ef-
fective in trapping PARPs to DNA. PARP trapping is synergistic in combi-
nation with alkylating agents and PARP catalytic inhibition synergizes with 
topoisomerase inhibitors. Despite synergism between PARP inhibition and 
cytotoxic agents under investigation, the optimal PARPi-chemotherapy 
combination for evaluation in TNBC remains to be established. 
olaparib improves PFS 
and reduces risk of 
progression 
 
 
not all patients respond 
and some without 
gBRCAm respond; no 
established biomarker 
for response or 
resistance screening 
mechanisms of 
resistance 
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [48, 49] 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
Olaparib breast cancer NC PFS 2b ≤6 months +2.8 
0.58 
0.43–0.80 
HR ≤0.65 AND Gain ≥1.5 
months 
3 
-13.9% grade 
3–4 AEs, 
dose reduc-
tions +19% 
ND x 3 
Original 
ESMO-
MCBS 
Olaparib breast cancer NC PFS 2b ≤6 months +2.8 
0.58 
0.43–0.80 
HR ≤0.65 AND Gain ≥1.5 
months 
3 x ND x 3 
Abbreviations: AJ = Adjustments, CI = confidence interval, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, PE = primary endpoint, PM = preliminary magnitude of 
clinical benefit grade, QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
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12 Appendix  
Table 4: Characteristics of the OlmpiAD trial [12, 45] 
Title: Assessment of the efficacy and safety of olaparib monotherapy versus physicians choice chemotherapy in the treatment of 
MBC patients with germline BRCA1/2 mutations (OlympiAD) [22] 
Study identifier NCT02000622, D0819C00003, EudraCT2013-005137-20, OlympiAD 
Design Randomized, controlled, open-label, multicentre, international (19 countries), phase III study  
Duration of main phase: April 7, 2014-November 27, 2015: randomized 302 patients 
December 9, 2016: final primary outcome data collected, 
77.5% of patients had BICR-assessed disease progression 
Duration of run-in phase: not applicable 
Duration of extension phase: 
Median duration of follow-up: 
not applicable 
Olaparib group: 14.5 months (2.1-29.5);  
Chemotherapy group: 14.1 months (0-28.2) 
Hypothesis 
Interventional/Treatment 
To evaluate the safety and efficacy of olaparib monotherapy versus physician’s choice chemother-
apy (capecitabine, vinorelbine or eribulin) by BICR-assessed PFS using RECIST 1.1    
Funding AstraZeneca 
Treatments groups 
 
Olaparib  
(n = 205 full analysis; n = 205 safety 
analysis) 
300 mg tablets twice daily until disease progression or un-
acceptable toxicity 
Chemotherapy (physician’s choice): 
(n = 97 full analysis; 91 safety analy-
sis) 
Capecitabine (n = 41) 
Eribulin (n = 34) 
Vinorelbine (n = 16) 
Until disease progression or unacceptable toxicity 
 
2500 mg/m2 oral daily for 14 days, every 21 days 
1.4 mg/m2 intravenously on days 1 and 8, every 21 days 
30 mg/m2 intravenously on days 1 and 8, every 21 days 
Notes 
After disease progression, treatment was at the discretion 
of the investigator 
Crossover to olaparib was not permitted 
Endpoints and definitions 
 Progression-free survival 
(primary endpoint) 
PFS 
Time from randomization to BICR-assessed disease pro-
gression (RECIST 1.1) or death by any cause; when approx-
imately 75% of patients have experienced progression. As-
sessed at baseline, every 6 weeks for 6 months then every 
12 weeks until progression for up to 7 years.  
Overall survival 
(secondary endpoint) OS 
Assessed at time of PFS analysis and when approximately 
60% of patients have died by any cause (average 15 
months after randomization); every 8 weeks following ob-
jective disease progression for up to 7 years.  
Second progression 
(secondary endpoint) PFS2 
Time from randomization to second progression, defined 
as objective radiological or symptomatic progression, or 
death. Assessed at time of PFS analysis and at final OS 
analysis; every 8 weeks for up to 7 years following first ob-
jective disease progression. 
Objective response rate 
(secondary endpoint) ORR 
ORR by BICR using RECIST 1.1 assessed at time of PFS 
analysis. Assessed at baseline, every 6 weeks for the first 6 
months, then every 12 weeks until objective disease pro-
gression up to 7 years.  
Health-related QoL 
(secondary endpoint) HRQoL 
Adjusted mean change from baseline in global QoL score 
from the EORTC-QLQ-C30 questionnaire completed at 
baseline and every 6 weeks until disease progression up to 
7 years.  
Safety and tolerability 
(secondary endpoint) AE Assessment of AEs graded by CTCAE (v4.0)  
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Title: Assessment of the efficacy and safety of olaparib monotherapy versus physicians choice chemotherapy in the treatment of 
MBC patients with germline BRCA1/2 mutations (OlympiAD) [22] 
Study identifier NCT02000622, D0819C00003, EudraCT2013-005137-20, OlympiAD 
Analysis description Primary Analysis 
A total of 230 PFS events were needed to provide 90% power to show a statistically significant dif-
ference in PFS between groups. Efficacy data were analysed on an intent-to-treat basis, and safety 
was assessed in all patients who received at least one dose of assigned treatment. Primary analysis 
of PFS was based on BICR and performed using a stratified log-rank test. Kaplan-Meier was used to 
generate time-to-event curves from which medians were calculated. For the primary endpoint, a 
log-rank test (stratified by hormone receptor status and previous chemotherapy use) was used to 
compare the Kaplan-Meier curved in two treatment groups. Hazard ratios and confidence intervals 
were estimated from the log-rank statistics. Exploratory sensitivity analyses were conducted to ex-
clude patients who did not receive the assigned treatment. OS was compared between groups us-
ing a stratified log-rank test.  The mean change from baseline in QLQ-C30 score across all time 
points was analysed using a mixed model for repeated measures. Kaplan-Meier curves were used to 
compare time to a clinically meaningful decrease in QLQ-C30 score between the two groups.  
Analysis population   
Inclusion 
 Adults (aged ≥18 years) with HER2-negative MBC that was 
hormone-receptor positive or triple negative 
 Deleterious or suspected deleterious germline BRCA muta-
tion; confirmed by centralized BRACAnalysis (Myriad Ge-
netics in all but 5 patients)  
 Histologically or cytologically confirmed breast cancer with 
evidence of metastatic disease 
 Prior therapy with an anthracycline and a taxane in either 
an adjuvant or metastatic setting 
 Prior platinum allowed as long as no breast cancer progres-
sion occurred on treatment or if given in adju-
vant/neoadjuvant setting at least 12 months from last dose 
to study entry elapsed 
 ER/PR breast cancer positive patients must have received 
and progressed on at least one endocrine therapy (adjuvant 
or metastatic) or have disease is believed to be inappropri-
ate for endocrine therapy 
 ECOG performance status 0-1 
 Adequate bone marrow, kidney and liver function 
 
Exclusion 
 Prior PARPi treatment 
 Patients with HER2-positive disease 
 More than 2 prior lines of chemotherapy for MBC 
 Untreated and/or uncontrolled brain metastases 
 Prior malignancy unless curatively treated and disease-free 
for > 5 years prior to entry. Prior adequately treated non-
melanoma skin cancer, in situ cancer of the cervix, DCIS or 
stage I grade 1 endometrial cancer were allowed. 
 Known HIV infection 
 Pregnant or breast-feeding women 
Characteristics 
Olaparib 
(n = 205) 
Chemotherapy 
(n = 97) 
Median age, years (range) 44 (22–76) 45 (24–68) 
Male sex, n (%) 5 (2.4) 2 (2.1) 
Race or ethnic group, n (%) 
Caucasian 
Asian 
Other 
 
134 (65.4) 
66 (32.2) 
5 (2.4) 
 
63 (64.9) 
28 (28.9) 
6 (6.2) 
ECOG performance status, n (%) 
0 
1 
 
148 (72.2) 
57 (27.8) 
 
62 (63.9) 
35 (36.1) 
BRCA mutation type, n (%) 
BRCA1 
BRCA2 
BRCA1 and BRCA2 
 
117 (57.1) 
84 (41.0) 
4 (2.0) 
 
51 (52.6) 
46 (47.4) 
0 (0) 
Hormone-receptor status, n (%) 
Hormone-receptor positive 
Triple negative 
 
103 (50.2) 
102 (49.8) 
 
49 (50.5) 
48 (49.5) 
New MBC, n (%) 26 (12.7) 12 (12.4) 
Previous chemotherapy for MBC, n (%) 146 (71.2) 69 (71.1) 
Previous platinum-based therapy for BC, n (%) 60 (29.3) 26 (26.8) 
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≥2 Metastatic sites, n (%) 159 (77.6) 72 (74.2) 
Location of metastasis, n (%) 
Bone only 
Other 
 
16 (7.8) 
189 (92.2) 
 
6 (6.2) 
91 (93.8) 
Measurable disease, n (%) 167 (81.5) 66 (68.0) 
QoL, n 
Baseline QLQ-C30 
191 
3.9±1.2 
73 
-3.6±2.2 
Abbreviations: AE = adverse event, BRCA1 = BReast CAncer gene 1, BRCA2 = BReast CAncer gene 2, CTCAE = Common Terminology 
Criteria for Adverse Events, BC = breast cancer, BICR = blinded independent central review, ECOG = Eastern Cooperative Oncology Group 
performance status; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, ER = 
estrogen-receptor, HER2 = human epidermal growth factor receptor type 2, MBC = metastatic breast cancer, ORR = objective response rate, OS 
= overall survival, PARPi = poly(adenosine diphosphate-ribose) polymerase inhibitor, PFS = progression-free survival, PFS2 = second progression, 
PR = progesterone-receptor, QoL = quality of life, RECIST = Response Evaluation Criteria in Solid Tumours 
 
 
 
Table 5: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [47] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: 2:1 olaparib vs IV chemotherapy by investigator 
or designate via a centralized interactive voice/web response system  (IVRS) which randomly as-
signed patients stratified by prior chemotherapy use in metastatic setting (yes/no), HR-status 
(HR+ /TNBC) and prior platinum therapy (yes/no).  
unclear 
Adequate allocation concealment: IVRS generated random allocation sequence; investigator de-
clared prior to randomization their choice of chemotherapy (capecitabine, vinorelbine or eribulin) 
unclear 
Blinding: 
Patient: open-label, patients unmasked to treatment assignment no 
Treating physician: open-label, investigators unmasked to treatment assign-
ment 
no 
Outcome assessment: open-label, tumour response assessed by investigator 
and BICR; exploratory post-hoc sensitivity analyses were conducted to ensure 
study conclusions were robust to deviations between the IVRS and stratifica-
tion factors and corresponding subgroups derived from electronic case reports 
unclear 
Selective outcome reporting unlikely: outcomes reported as specified in protocol; withdrawals and 
drop-outs reported 
no 
No other aspects which increase the risk of bias: industry funded the study, assisted with study 
design, data collection, analysis, interpretation, writing, and revisions 
yes 
Risk of bias – study level high 
Abbreviations: BICR = blinded independent central review 
 
 
